Jake Wintermute 🪵
2 years
My take on the recent crispr ruling is that bio, like tech before it, is starting to iterate faster than we can litigate
Crispr advanced 3 generations without a stable IP framework. In this world, companies that focus on execution will outrun companies that wait for exclusivity